Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient
Camillo Porta, Chiara Broglia, Francesca Negri – 25 January 2019
A Large‐Scale Multicenter Study Validates Aldo‐Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma
Xu Ye, Cunyan Li, Xuyu Zu, Minglin Lin, Qiang Liu, Jianghua Liu, Guoguo Xu, Zhiyong Chen, Yongliang Xu, Long Liu, Diteng Luo, Zhe Cao, Guiyuan Shi, Zirui Feng, Hongyu Deng, Qianjin Liao, Chuan Cai, Duan‐Fang Liao, Jing Wang, Junfei Jin, Deliang Cao – 23 January 2019 – Aldo‐keto reductase family 1 member B10 (AKR1B10) is a secretory protein overexpressed in hepatocellular carcinoma (HCC). We aimed to evaluate AKR1B10 as a serum marker for detection of HCC.
Small Dense Low‐Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients
Mohammad Bilal Siddiqui, Tamoore Arshad, Samarth Patel, Emily Lee, Somaya Albhaisi, Arun J. Sanyal, R. Todd Stravitz, Carolyn Driscoll, Richard K. Sterling, Trevor Reichman, Chandra Bhati, Mohammad Shadab Siddiqui – 23 January 2019 – Cardiovascular disease (CVD) is an important cause of morbidity and mortality after liver transplantation (LT). Although LT is associated with dyslipidemia, particularly atherogenic lipoprotein subparticles, the impact of these subparticles on CVD‐related events is unknown.
Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests
Hiam Chemaitelly, Sarwat Mahmud, Silva P. Kouyoumjian, Zaina Al‐Kanaani, Joumana G. Hermez, Laith J. Abu‐Raddad – 23 January 2019 – Expanding hepatitis C virus (HCV) treatment coverage is challenged by limited testing and diagnosis. This study assessed the risk of exposure, for the Middle East and North Africa, by population, yields of testing, and program efficiency of testing strategies. A standardized and systematically assembled database of 2,542 HCV antibody prevalence studies on 49 million individuals was analyzed.
Left Ventricular Longitudinal Contractility Predicts Acute‐on‐Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt
Christian Jansen, Anna Schröder, Robert Schueler, Jennifer Lehmann, Michael Praktiknjo, Frank E. Uschner, Robert Schierwagen, Daniel Thomas, Sofia Monteiro, Georg Nickenig, Christian P. Strassburg, Carsten Meyer, Vicente Arroyo, Christoph Hammerstingl, Jonel Trebicka – 22 January 2019 – Acute deterioration of liver cirrhosis (e.g., infections, acute‐on‐chronic liver failure [ACLF]) requires an increase in cardiac contractility. The insufficiency to respond to these situations could be deleterious.
Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
Akira Hiramatsu, Hiroshi Aikata, Shinsuke Uchikawa, Kazuki Ohya, Kenichiro Kodama, Yuno Nishida, Kana Daijo, Mitsutaka Osawa, Yuji Teraoka, Fumi Honda, Yuki Inagaki, Kei Morio, Reona Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Michio Imamura, Junko Tanaka, Kazuaki Chayama – 22 January 2019 – Although the effect of levocarnitine (L‐carnitine) on hyperammonemia has been reported in patients with liver cirrhosis (LC), its effect on sarcopenia remains to be elucidated.
Oxaloacetate Protects Rat Liver From Experimental Warm Ischemia/Reperfusion Injury by Improving Cellular Energy Metabolism
Grégory Merlen, Valérie‐Ann Raymond, Shamir Cassim, Pascal Lapierre, Marc Bilodeau – 21 January 2019 – Liver ischemia/reperfusion injury (IRI) is an important cause of liver damage especially early after liver transplantation, following liver resection, and in other clinical situations. Using rat experimental models, we identified oxaloacetate (OAA) as a key metabolite able to protect hepatocytes from hypoxia and IRI. In vitro screening of metabolic intermediates beneficial for hepatocyte survival under hypoxia was performed by measures of cell death and injury.
E‐cigarettes and Western Diet: Important Metabolic Risk Factors for Hepatic Diseases
- Read more about E‐cigarettes and Western Diet: Important Metabolic Risk Factors for Hepatic Diseases
Kamrul M. Hasan, Theodore C. Friedman, Xuesi Shao, Meher Parveen, Carl Sims, Desean L. Lee, Jorge Espinoza‐Derout, Indrani Sinha‐Hikim, Amiya P. Sinha‐Hikim – 21 January 2019 – The use of electronic nicotine delivery systems (ENDS), also known as e‐cigarettes, with a variety of e‐liquids/e‐juices, is increasing at an alarming rate among adolescents who do not realize the potential harmful health effects. This study examines the harmful effects of ENDS on the liver.
Efficacy of Granulocyte Colony‐stimulating Factor in the Management of Steroid‐Nonresponsive Severe Alcoholic Hepatitis: A Double‐Blind Randomized Controlled Trial
Saggere Muralikrishna Shasthry, Manoj Kumar Sharma, Varsha Shasthry, Apurva Pande, Shiv Kumar Sarin – 21 January 2019 – Severe alcoholic hepatitis (SAH) is often a progressive disease with high mortality and limited steroid responsiveness. Management options of steroid nonresponsive SAH (day 7 Lille score > 0.45) are limited. We assessed the efficacy and safety of granulocyte colony‐stimulating factor (G‐CSF) in steroid nonresponders.